![updated_logo_0.jpg](./Home _ Together Trial_files/updated_logo_0.webp)
![](./Home _ Together Trial_files/4e5c71_c1931af6d16844da90c27406652bf6ad_mv2.webp)
![universiteit_stellenbosch_university_01.](./Home _ Together Trial_files/universiteit_stellenbosch_university_01_.webp)
![0.png](./Home _ Together Trial_files/0.webp)
![Cytel-Logo-png-format-300x171.png](./Home _ Together Trial_files/Cytel-Logo-png-format-300x171.webp)
![Cytel-Logo-png-format-300x171.png](./Home _ Together Trial_files/Cytel-Logo-png-format-300x171(1).webp)
Most clinical trials for COVID-19 are based in higher-income country acute care hospitals (COVID-19 Trial Tracker). Many of these trials exclude marginalized poverty stricken populations, such as people with severe malnutrition, people living with HIV (PLHIV) and people with active or latent tuberculosis (TB).
The goal of the TOGETHER trial is to determine the effectiveness and safety of the initial treatments of high-risk adults within 48 hours of being diagnosed with SARS-CoV-2 infection, who are not requiring hospitalization, Using repurposed, widely availiable, and economically feasible drugs. This trial uses a novel adaptive platform design.
This trial is based in Brazil and South Africa and will focus on four treatment arms against a placebo arm.
![Trial schemas - v0.4.jpg](./Home _ Together Trial_files/Trial schemas - v0_4.webp)
Concurrent with all sites, we will work together to generate comparative data. Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients and ineffective treatment can be ceased and resources re-allocated to more encouraging leads. The TOGETHER Trial team will constantly review information on new drugs and include promising ones in the trial.
![](./Home _ Together Trial_files/4e5c71_d57e4374039d422db7acf4949bdddf7b_mv2.webp)
Belo Horizonte, Brazil
Cape Town, South Africa
![1280px-Bill-&-Melinda-Gates-Foundation-L](./Home _ Together Trial_files/1280px-Bill-&-Melinda-Gates-Foundation-L.webp)
This trial is supported with seed funding from the Bill and Melinda Gates Foundation.
All study documents, including the participant information sheet and consent form, can be downloaded from the For Staff area of the site.
Contact us
Email:
Phone: 604-294-3823